Molecular Partners

Contributing Author

Recent Articles by Molecular Partners

17 hours	Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma MOLN GlobeNewswire
Jul-15	Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference MOLN GlobeNewswire
Jul-06	Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics MOLN GlobeNewswire
Jul-02	Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 MOLN GlobeNewswire
May-30	Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 MOLN GlobeNewswire
May-26	Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit MOLN GlobeNewswire
May-12	Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 MOLN GlobeNewswire
May-04	Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences MOLN GlobeNewswire
May-01	Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling MOLN GlobeNewswire
Apr-19	Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 MOLN GlobeNewswire
Apr-14	Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting MOLN GlobeNewswire
Mar-23	Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors MOLN GlobeNewswire
Mar-19	Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes MOLN GlobeNewswire
Mar-17	Molecular Partners to Hold Three Poster Presentations at AACR 2026 MOLN GlobeNewswire
Mar-12	Molecular Partners Reports Highlights and Financial Results for Full Year 2025 MOLN MOLN -10.40% GlobeNewswire
Feb-26	Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results MOLN GlobeNewswire
Feb-26	Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics MOLN GlobeNewswire
Feb-02	Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 MOLN +7.53% GlobeNewswire
Jan-11	Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference MOLN GlobeNewswire
Dec-18	Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference MOLN GlobeNewswire
Dec-11	Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics MOLN GlobeNewswire
Dec-07	Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting MOLN GlobeNewswire
Nov-12	Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action MOLN GlobeNewswire
Nov-03	Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 MOLN +12.42% GlobeNewswire
Nov-03	Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting MOLN +12.42% GlobeNewswire
Oct-30	Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 MOLN GlobeNewswire
Aug-25	Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 MOLN +14.85% MOLN -7.71% GlobeNewswire
Aug-21	Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics MOLN GlobeNewswire
Jun-22	Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 MOLN GlobeNewswire
Jun-11	Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 MOLN MOLN +8.03% GlobeNewswire
Jun-10	Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway MOLN GlobeNewswire
May-19	Molecular Partners to Present at Upcoming Investor Conferences MOLN GlobeNewswire
May-15	Molecular Partners Reports Financial Results and Highlights from Q1 2025 MOLN GlobeNewswire

Molecular Partners

Recent Articles by Molecular Partners

Upgrade your Finviz experience